Seoul, South Korea

Cheol Hee Won

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 1.4

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Cheol Hee Won: Innovator in Immunotherapy and Flavivirus Treatment

Introduction

Cheol Hee Won is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the fields of immunotherapy and infectious disease treatment, holding a total of five patents. His innovative work focuses on developing effective solutions for cancer and various immune diseases.

Latest Patents

One of his latest patents is an immunoreactant carrier, which is designed to stably deliver various immunoreactive substances, including antibodies and cytokines, to target sites. This invention exhibits excellent immunotherapeutic effects, making it a valuable composition for immunotherapy in the prevention or treatment of cancer and various immune diseases. Another notable patent is a pharmaceutical composition for the prevention or treatment of flavivirus infection. This method involves administering a composition that includes several antibiotics and antiviral agents, which can effectively inhibit the growth or kill various species of the flavivirus genus.

Career Highlights

Cheol Hee Won has worked with notable organizations, including Lemonex Inc. and Seoul National University. His experience in these institutions has allowed him to advance his research and contribute to significant medical innovations.

Collaborations

He has collaborated with esteemed colleagues such as Jun Hui Kim and Dal Hee Min, further enhancing the impact of his work in the scientific community.

Conclusion

Cheol Hee Won's contributions to immunotherapy and flavivirus treatment highlight his role as an influential inventor. His innovative patents and collaborations continue to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…